GIUV2019-446
The Joint Research Unit on Experimental Hepatology was established in 2008 through a research agreement between the Universitat de València and the La Fe Hospital Research Foundation, integrating teaching and research staff from both the Department of Biochemistry and Molecular Biology of the UVEG and the Health Research Institute of La Fe Hospital. Its main objective is translational research in hepatology. Based on the study of the cellular and molecular biology of hepatocytes, the group conducts in-depth research into problems of clinical relevance in hepatology, using complex cellular models capable of mimicking the behaviour of the human liver. In addition, with the support of advanced analytical technologies, we develop new diagnostic and therapeutic strategies. More specifically, the group carries out relevant and pioneering research activity in:
The development of human liver cell models with a differentiated phenotype, which are able to reproduce the pathophysiology of hepatocytes.
The study of drug-induced hepatotoxicity, trying to elucidate the molecular mechanisms and genes involved, and searching for new biomarkers for clinical translation.
Research into...The Joint Research Unit on Experimental Hepatology was established in 2008 through a research agreement between the Universitat de València and the La Fe Hospital Research Foundation, integrating teaching and research staff from both the Department of Biochemistry and Molecular Biology of the UVEG and the Health Research Institute of La Fe Hospital. Its main objective is translational research in hepatology. Based on the study of the cellular and molecular biology of hepatocytes, the group conducts in-depth research into problems of clinical relevance in hepatology, using complex cellular models capable of mimicking the behaviour of the human liver. In addition, with the support of advanced analytical technologies, we develop new diagnostic and therapeutic strategies. More specifically, the group carries out relevant and pioneering research activity in:
The development of human liver cell models with a differentiated phenotype, which are able to reproduce the pathophysiology of hepatocytes.
The study of drug-induced hepatotoxicity, trying to elucidate the molecular mechanisms and genes involved, and searching for new biomarkers for clinical translation.
Research into non-alcoholic fatty liver disease. With a particular emphasis on
The development of new strategies for diagnosis, monitoring and clinical prognosis in drug-induced hepatotoxicity, and their validation in clinical trials.
Improving cell transplantation as a therapy for certain liver diseases
[Read more][Hide]
[Read more][Hide]
- Desarrollar modelos celulares hepaticos humanos con un fenotipo adulto diferenciado y una repuesta fisiopatologica similar a la observada in vivo.
- Investigar los mecanismos moleculares de la hepatotoxicidad por farmacos, buscando nuevos biomarcadores predictivos de esteatosis y colestasis iatrogenica.
- Elucidar nuevos mecanismos transcripcionales implicados en la enfermedad del higado graso no alcoholico, buscando las vias distintivas de la esteatosis metabolica y la causada por medicamentos.
- Desarrollar nuevos procedimientos de diagnostico, seguimiento y pronostico clinico para la lesion hepatica inducida por medicamentos, y validarlos en ensayos clinicos.
- Avanzar en la investigacion del trasplante celular como alternativa al trasplante ortotopico de higado y como terapia para determinadas enfermedades hepaticas.
- Hepatotoxicity.The main objective of this line is to investigate the molecular mechanisms of drug hepatotoxicity. These studies are a very valuable aid in the preclinical stages of the development of new drugs, as well as to elucidate hepatic adverse reactions to drugs already on the market. They are also essential for finding new biomarkers (microRNAs, metabolites) to, for example, predict steatosis or cholestasis, which are two of the most frequent manifestations of drug-induced liver injury.
- Advanced human liver cell models.In this line, the main objective is to develop and improve human liver cell models in vitro so that they maintain a differentiated adult phenotype and show a pathophysiological response similar to that observed in vivo.
- New molecular mechanisms in non-alcoholic fatty liver disease.The main objective of this line is to better understand, from a molecular point of view, non-alcoholic fatty liver disease. This disease has pandemic overtones as it affects a high percentage of our population. The difficulty lies in the fact that it is a multifactorial disease, with diverse and incompletely understood aetiological mechanisms. The group is mainly investigating transcriptional causal mechanisms. We are also interested in the specific pathways leading to metabolic steatosis and steatosis caused by xenobiotics, such as drugs. From basic knowledge we hope to find predictive and diagnostic biomarkers that allow better management of this disease.
- Translational research in hepatotoxicity and cell therapy.The results of the basic research carried out by the group are always analysed from multiple angles with the aim of seeking their clinical application. Within this more translational facet of our research, our main objectives are to develop new diagnostic, monitoring and clinical prognostic procedures for drug-induced liver injury. This research involves setting up several clinical trials to validate the proposed procedures. Another priority objective is to obtain induced stem cells from patients with various liver diseases for their correction and subsequent use in cell therapy. In this same context, the group has also pioneered human hepatocyte transplants as an alternative to orthotopic organ transplantation.
| Name | Nature of participation | Entity | Description |
|---|---|---|---|
| RAMIRO JOVER ATIENZA | Director | Universitat de València | |
| Research team | |||
| JOSE VICENTE CASTELL RIPOLL | Member | Universitat de València | |
| MARIA TERESA DONATO MARTIN | Member | Universitat de València | |
| MARTA MORENO TORRES | Member | Universitat de València | |
| MARIA JOSE GOMEZ-LECHON MOLINER | Collaborator | INSTITUTO DE INVESTIGACION SANITARIA LA FE (VALENCIA) | head of section/service |
- -
- Biochemistry and Molecular Biology
- Hepatotoxicidad, mecanismos moleculares, necrosis, apoptosis, alteraciones metabólicas, biomarcadores, transcriptómica, metabolómica.
- hepatocytes, continuous liver lines, cell cultures, 2D cultures, 3D cultures, biomaterials, spheroids, organoids, differentiated hepatic phenotype, cellular response to drugs, inter-individual variability, idiosyncrasies
- Non-alcoholic fatty liver disease, metabolic steatosis, iatrogenic steatosis, transcriptional mechanisms, predictive biomarkers
- Lesión hepática por medicamentos. Biomarcadores. Diagnóstico y seguimiento clínico. Transplante de hepatocitos. Celulas madre inducidas. Terapia génica. Terapia celular.
